{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T15:03:05Z","timestamp":1775228585122,"version":"3.50.1"},"reference-count":0,"publisher":"Therapeutic Guidelines Limited","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aust Prescr"],"DOI":"10.18773\/austprescr.2019.029","type":"journal-article","created":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T01:08:31Z","timestamp":1555981711000},"page":"102","source":"Crossref","is-referenced-by-count":0,"title":["New Drug: Cerliponase alfa for neuronal ceroid lipofuscinosis type 2 disease"],"prefix":"10.18773","volume":"42","member":"39051","published-online":{"date-parts":[[2019,4,24]]},"container-title":["Australian Prescriber"],"original-title":[],"link":[{"URL":"https:\/\/australianprescriber.tg.org.au\/articles\/cerliponase-alfa-for-neuronal-ceroid-lipofuscinosis-type-2-disease.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T14:17:43Z","timestamp":1775225863000},"score":1,"resource":{"primary":{"URL":"https:\/\/australianprescriber.tg.org.au\/articles\/cerliponase-alfa-for-neuronal-ceroid-lipofuscinosis-type-2-disease.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,24]]},"references-count":0,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,6,3]]}},"URL":"https:\/\/doi.org\/10.18773\/austprescr.2019.029","relation":{},"ISSN":["1839-3942"],"issn-type":[{"value":"1839-3942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,24]]}}}